Document is current

Article History

Received: 14 October 2022

Accepted: 16 May 2023

First Online: 12 July 2023

Competing interests

: S.A.C.: Natera (travel; local principal investigator (PI), funding to the institution (inst)), Kallyope (consultant), Istari Oncology (consultant), Pfizer (consultant; local PI, inst), Taiho (consultant), Delcath (consultant), Bayer (consultant), Merck/EMD Serono (local PI, inst), Isofol (local PI, inst), Polaris (local PI, inst), Boston Biomedical/Sumitomo Dainippon Pharma (local PI, inst), Faeth (local PI, inst) and Tempus (local PI, inst). M.C.L.: Natera (Employment and stocks), Eisai (grants and contracts to Mayo), Exact Sciences (grants and contracts to Mayo), Genentech/Roche (grants and contracts to Mayo), GRAIL (grants and contracts to Mayo; advisory board with compensation to Mayo), Merck (grants and contracts to Mayo; advisory board with compensation to Mayo), Novartis (grants and contracts to Mayo), Seattle Genetics (grants and contracts to Mayo; advisory board with compensation to Mayo), Tesaro (grants and contracts to Mayo), AstraZeneca (travel; advisory board with compensation to Mayo), Genomic Health (travel; grants and contracts to Mayo; advisory board with compensation to Mayo), Ionis (travel; advisory board with compensation to Mayo), Celgene (advisory board with compensation to Mayo), Pfizer (advisory board with compensation to Mayo) and Syndax (Advisory board with compensation to Mayo). A.A.: Natera (employment and stocks).